We aimed to identify specific metabolomic changes and biomarkers for the differential clinical diagnosis of different subtypes of moyamoya disease (MMD). We conducted an pseudotargeted metabolomics analysis and pseudotargeted metabolomics analysis revealed decreased LPC expression in patients wit...
The perturbations of the gut microbiota and metabolites are closely associated with the progression of inflammatory bowel disease (IBD). However, inconsistent findings across studies impede a comprehensive understanding of their roles in IBD and their potential as reliable diagnostic biomarkers. ...